FDA approves new monthly injection for schizophrenia treatment
The FDA approved a new once-monthly subcutaneous injectable form of olanzapine for schizophrenia in adults. The drug, previously available in oral form, is now offered as a different formulation.
Adults with schizophrenia may benefit; evidence comes from regulatory approval, not clinical trial results.
New formulation details
The new formulation is a subcutaneous injection, administered once a month, and is marketed as Weltruza by Teva Pharmaceuticals.
Existing drug approval
Olanzapine has been used in oral form for decades, but this is the first approval for a monthly injectable version.
Common questions
What is the new treatment for schizophrenia?
A once-monthly subcutaneous injectable form of olanzapine, approved by the FDA and marketed as Weltruza.
Sources
- Decades-Old Schizophrenia Drug Wins Approval for New Formulation MedPage Today · medpagetoday.com
Headlines and links belong to the publishers listed above. The summary above is written by The Health Brief; see how this works.
